Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer ...

Core Insights - Rapid Micro Biosystems, Inc. is participating in the Stifel 2025 Healthcare Conference in New York, NY on November 11, 2025 [1][2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Insights - Rapid Micro Biosystems, Inc. will release its third quarter 2025 financial results on November 7, 2025, before market opening [1] - The management team will host a webcast conference call at 8:30 a.m. ET on the same day, which will be accessible on the company's website [2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Insights - Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, a company specializing in automation solutions for microbial quality control in healthcare product manufacturing [1][3][5] - Rapid Micro's Growth Direct platform enhances operational efficiency and data integrity, enabling faster and more accurate results in critical applications such as environmental monitoring and sterility testing [2][5] Company Overview - Trinity Capital Inc. is an alternative asset manager focused on private credit markets, having deployed over $4.7 billion across more than 420 investments since its inception in 2008 [4] - Rapid Micro Biosystems provides automation solutions that modernize manual microbial quality control testing workflows, significantly impacting biopharma manufacturing processes [5] Strategic Goals - The new capital from Trinity Capital will support Rapid Micro's global expansion of the Growth Direct platform and drive gross margin improvements through cost reductions and increased manufacturing efficiencies [3][4] - Rapid Micro aims to strengthen its financial position and focus on long-term revenue growth, margin expansion, and shareholder value enhancement [4]

Company Overview - Singular Genomics has raised approximately $450 million [10] - The company held $133 million in cash as of June 30, 2024 [10] - The company has approximately 195 employees [12] - The company has around 300 issued and pending patents [10, 12] Market Opportunity - The Next Generation Sequencing market is estimated at $7 billion in 2023, projected to reach $20 billion by 2030 [17] - The Spatial Sequencing market is estimated at $2 billion in 2023, projected to reach $11 billion by 2030, representing a 23% CAGR [19, 46] G4 Platform - The G4 platform offers flexibility with 1-4 flow cells and 16 lanes [28] - The G4 platform can achieve run times of 8-24 hours [28] - The G4 platform can produce up to 480 Gb output [28] G4X Platform - The G4X platform has a 40 cm² imaging area [77, 82] - The G4X platform offers high-throughput spatial sequencing with multiomic capabilities, including RNA, protein, and H&E [82]

Company Overview - Rapid Micro Biosystems, Inc. is an innovative life sciences technology company focused on providing automation solutions for the efficient manufacturing and safe release of healthcare products [3] - The company specializes in products such as biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The flagship product, Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing [3] Financial Results Announcement - The company will release its first quarter 2025 financial results on May 9, 2025, prior to market opening [1] - A webcast conference call will be hosted by the management team at 8:30 a.m. ET on the same day [2] - The live audio webcast will be available on the company's website and will be archived for replay [2] Operational Efficiency - The Growth Direct system automates quality control processes, leading to faster results, greater accuracy, and increased operational efficiency [3] - The system enhances compliance with data integrity regulations and supports quicker decision-making for healthcare product supply [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands [3]